Definium Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapeutics and brain-health medicines for psychiatric and neurodevelopmental disorders, including generalized anxiety disorder, autism spectrum disorder, and related conditions. Headquartered in New York, NY, the company operates primarily in the United States with a focus on late-stage clinical development and preparation for potential commercialization. Main Products and Services - Lead product candidates: DT120 (also referred to as DT120 ODT), an orally disintegrating tablet formulation in Phase 3 programs for generalized anxiety disorder (GAD) and major depressive disorder (MDD); MM120 (formerly MM-120), a lysergide D-tartrate derivative in development for generalized anxiety disorder and a subperceptual dosing approach for ADHD; DT402 (R-enantiomer of MDMA), studied in Phase 2a trials for autism spectrum disorder (ASD) core symptoms. - Early-stage pipeline: DT400-series programs and related compounds addressing brain health and mood disorders; preclinical and Phase 1/2 activities aimed at expanding therapeutic indications beyond anxiety and ASD. - Diagnostic and companion capabilities (where applicable): development programs aligned with precision psychiatry and patient stratification to optimize responder profiles and treatment regimens. - Clinical development services: design and execution of multi-center Phase 2/3 trials; regulatory strategy and interactions; data management, biostatistics, and pharmacovigilance for late-stage programs. - Pharmaceutical development enablement: formulation optimization, drug delivery science (including oral disintegrating tablets), and scaling considerations for potential commercialization. Latest Major Company Changes - Rebranding and strategic refocus: MindMed rebrands to Definium Therapeutics, signaling a shift toward a late-stage psychiatry pipeline and commitment to advancing three Phase 3 readouts in 2026, anchored by DT120 ODT for GAD and MDD, with a broader late-stage program footprint. - Pipeline advancement and late-stage emphasis: (>2026) Solidification of multiple Phase 3 trials in GAD and MDD, with additional Phase 3 readouts anticipated in 2026, reinforcing a strategy to prepare for potential commercialization and a best-in-class care model. - Ongoing expansion of late-stage and mid-stage assets: Continued progression of DT120 toward regulatory milestones, alongside the continuation of MM120 and DT402 programs, indicating an expanded portfolio and potential new indications or dosing paradigms. Industry context and business segments - Industry: Biopharmaceuticals with emphasis on psychiatric and neurological disorders, leveraging psychedelic-inspired therapeutics as a core strategic axis. - Business segments: Late-stage clinical development (Phase 3 programs for GAD and MDD), mid-stage and early-stage research (DT402 for ASD; MM120 for GAD/ADHD), and preparation for potential commercialization including operations and strategic partnerships. Geographic operations and corporate structure - Headquarters: New York, New York, United States; primary operating focus on U.S.-based clinical programs with regulatory interactions in major global markets. - Subsidiaries/affiliates: Corporate entity maintains oversight of global development programs, with potential regional partnerships or licensing discussions as part of a broader commercialization strategy, consistent with late-stage pharma company structures (as described in public disclosures). Founding year and corporate evolution - Founding background: Originally MindMed, established in 2010, transitions to Definium Therapeutics in 2026 as part of a strategic rebranding to emphasize a late-stage psychiatry pipeline; headquarters remain in the United States while pursuing global development objectives. Notes - The description reflects publicly disclosed information through early-2026 press releases and industry coverage, including rebranding announcements and Phase 3 program outlines; readers should consult the company’s investor relations materials for the most current clinical readouts and regulatory status. References indicate the rebranding and Phase 3-readout focus as central updates to the company’s profile in 2026.
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
Definium Therapeutics Announces New Employee Inducement Grants
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biotech ETF Index Surges 10% After Rebalance
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program